THYROCARENSEThyrocare Technologies LimitedHighNeutral
Announced Thu, 7 May · 19:53 IST

Thyrocare Technologies Limited has informed the Exchange regarding change in Directors of the Company.

Management Changes View source PDF

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.3%1-day move
₹472.50
prior close
₹493.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.2+5.4+5.2+3.0+1.3-0.1+1.2-0.5-2.4-0.7+10.1+14.2+10.9
Up moveDown movePending
AI summary

Thyrocare Technologies held its Board meeting on May 7, 2026, approving several key matters. The Board recommended a final dividend of Rs. 7 per share for FY 2025-26, bringing the total dividend for the year to Rs. 9.33 per share (post bonus adjustment). The company appointed Price Waterhouse Chartered Accountants LLP as the new statutory auditor for a 5-year term, replacing M S K A & Associates LLP upon completion of their term. Mr. Rahul Franklin Guha was re-appointed as Chairman, MD & CEO for another 5 years. Two directors resigned citing pre-occupation: Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah. Two new directors were appointed: Mr. Uday Patel Kadam and Mr. Gaurav Verma, both associated with API Holdings Limited. The Board also approved an investment of up to Rs. 5.50 crores in Think Health Diagnostics Private Limited (a wholly owned subsidiary) and alterations to the Memorandum of Association to expand the company's objects clause to include broader healthcare and diagnostics activities.

Likely market impact

The resignation of two non-executive directors and appointment of two new directors indicates board composition changes. The re-appointment of the CEO provides continuity in leadership. The dividend recommendation and investment in subsidiary signal positive shareholder returns and expansion plans.